



Reagan-Udall Foundation for the FDA Announces Appointment of Three New Board Members

October 9, 2018

Washington, DC—The [Reagan-Udall Foundation for the Food and Drug Administration](#), an independent nonprofit organization that works to advance regulatory science and the scientific mission of the FDA announces the appointment of three new Board members: Andrew C. von Eschenbach, M.D., former FDA Commissioner; Edward John Allera JD, pharmacist and attorney with expertise in FDA regulation and biotechnology; and, Lynne Zydowsky, Ph.D., a biotechnology and life science executive. All three bring decades of leadership and experience to their roles.

“We are thrilled to welcome these new Board members to the Foundation’s leadership team,” said Ellen V. Sigal, Ph.D., Chair of the Foundation Board of Directors and Friends of Cancer Research (FOCR) founder. “Their diverse perspectives and experiences will enhance our ongoing efforts to create innovative programs that support the important work we do on behalf of the community and the FDA.”

[Edward John Allera, J.D.](#) has devoted his career to health care, as both a pharmacist and an attorney. He began his career at the FDA, where he served as an Associate Chief Counsel. Additionally, his passion for fostering regulatory policy and academic collaboration is evident through his work with the West Virginia University Health Sciences Center’s School of Pharmacy and FDA’s Office of Oncology in creating a fellowship that introduces Pharm.Ds into FDA’s regulatory system. He serves as the co-chair of the Buchanan, Ingersoll & Rooney PC’s FDA/Biotechnology Group where he counsels clients on new product development and business opportunities in the areas of pharmaceuticals, hi-tech products, medical devices, and food and cosmetics. Because of his ability to integrate science and the law, he is highly-respected by clients and colleagues in the pharma/biotech industry.

[Andrew C. von Eschenbach, M.D.](#) entered government service after an outstanding career over three decades as a physician, surgeon, oncologist and executive. He currently serves as President of Samaritan Health Initiatives, Inc., as an Adjunct Professor at University of Texas MD Anderson Cancer Center, as a Senior Fellow at the Milken Institute and previously served as Chair of the Congressional Advisory Panel on 21st Century Cures. He is the 20th Commissioner of the FDA (2005-09). At the FDA, he championed an agenda to modernize the agency. Prior to that he served as the Director of the National Cancer Institute (NCI) at the National Institutes of Health (NIH), where he set an ambitious goal to eliminate the suffering and death due to cancer by rapid acceleration and integration of the discovery-development-delivery continuum. Dr. von Eschenbach has authored more than 300 scientific papers and has received numerous professional awards and honors. In 2006, he was named one of “The TIME 100: The People Who Shape Our World.”

[Lynne Zydowsky, Ph.D.](#) is an experienced executive in the life science industry who has been involved in the launching and building of many successful companies. Her biotechnology experience spans all aspects of corporate and business development, operations, and finance. With over 20 years of industry

experience, she played a key role in the development of the Alexandria Summit which convenes leading visionaries from the biotechnology, pharmaceutical, and technology industries to address some of the most important global health challenges. In addition, Dr. Zydowsky is on the Board of Trustees at Butler University and the Discovery Council for Harvard Medical School. She currently serves as the President and Co-Founder of Alexandria Summit and the Chief Science Officer of Alexandria Real Estate Equities, Inc. Alexandria Venture Investments.

About the Reagan-Udall Foundation for the FDA

The Reagan-Udall Foundation for the FDA is an independent 501(c)(3) not-for-profit organization created by Congress for the purpose of advancing regulatory science to support the FDA's mission. For additional information about the Foundation, please visit <https://reaganudall.org/>.

###

Media Contact Information (not for publication)

Lea Ann Browning-McNee
Director of Marketing and Communications
Reagan-Udall Foundation for the FDA
Lamcnee@reaganudall.org
202-849-2071 (office)
301-509-1846 (mobile)